Latest Articles

Publication Date
Bowel endometriosis: from pathogenesis to clinical management.

Bowel involvement is a severe manifestation of deep endometriosis that affects approximately 8-12% of women with endometriosis. Bowel endometriosis is most commonly localised in the rectosigmoid colon and frequently coexists …

Published: July 3, 2026, midnight
Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen …

Published: June 25, 2026, midnight
Multiple recurrences of postmenopausal endometriosis associated with estrogen pellet therapy: clinical implications for hormone therapy and surgical management.

To challenge the perception that endometriosis uniformly regresses after menopause by presenting the case of repeated, pathology-confirmed symptomatic recurrences spanning two decades after menopause, and to emphasize key considerations for …

Published: June 9, 2026, midnight
Histological and immunohistochemical characteristics of superficial peritoneal endometriotic lesions of clinical responders and non-responders to dienogest treatment.

Are there histological and immunohistochemical patterns of superficial peritoneal endometriotic lesions of symptomatic patients that characterize non-response to dienogest treatment and may suggest progesterone resistance?

Published: April 18, 2026, midnight
Medical Treatment for Endometriosis: One Size Does Not Fit All.

Endometriosis is associated with nociceptive pain, as well as peripheral and central sensitization. Evidence-based treatment suggestions for controlling endometriosis should be based on the convergence of the best scientific evidence, …

Published: March 21, 2026, midnight
Progestins - a review of clinical application in gynecology.

Progestins are a group of substances with a wide range of applications. They are classified into pregnanes, estranes, and gonanes, and further divided into four generations based on their testosterone …

Published: Dec. 12, 2025, midnight
In utero exposure to synthetic sex hormones and their multigenerational impact on neurodevelopmental disorders: Endocrine disruptors as neuroendocrine disruptors.

Synthetic sex hormones, estrogens and/or progestogens, have been widely administered without sufficient long-term studies for decades to millions of pregnant women around the world and although most were banned in …

Published: April 1, 2025, midnight
Clinical effectiveness of progestogens compared to combined oral contraceptive pills in the treatment of endometriosis: A systematic review and meta-analysis.

Endometriosis involves the growth of endometrium-like cells outside the uterus, affecting reproductive-aged women. Symptoms such as dysmenorrhea, pelvic pain, and infertility significantly impair quality of life. Among therapeutic options, progestogens …

Published: Jan. 23, 2025, midnight
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Recent Trends in Medical Management of Endometriosis.

Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the …

Published: Dec. 26, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!